Admission fibrinogen-to-albumin ratio and mortality in older adults hospitalized with pneumonia: a retrospective cohort study

老年肺炎住院患者入院时纤维蛋白原/白蛋白比值与死亡率的关系:一项回顾性队列研究

阅读:1

Abstract

BACKGROUND: Pneumonia remains a major cause of hospitalization and death among older adults worldwide. Simple bedside biomarkers that capture the host response to infection may help support early risk stratification in routine care. The fibrinogen-to-albumin ratio (FAR) integrates information on inflammation, coagulation, and nutritional status. We explored whether the admission FAR is associated with 30- and 365-day all-cause mortality in older adults hospitalized with pneumonia. METHODS: We conducted a single-center retrospective cohort study of patients aged ≥ 65 years who presented to a fever clinic with acute fever and were subsequently admitted to general medical wards with radiologically confirmed pneumonia in 2021. FAR was calculated from fibrinogen and albumin measured within 24 h of admission. Associations between FAR and 30- and 365-day all-cause mortality were analyzed using multivariable Cox regression and restricted cubic splines. RESULTS: Of the 339 included older adults with pneumonia, 47 (13.9%) died within 30 days and 78 (23.0%) died within 365 days after admission. In fully adjusted Cox models, a higher admission FAR was associated with increased mortality, with a hazard ratio (HR) per 0.10-unit increase of 1.62 (95% CI, 1.07–2.46) for 30-day all-cause mortality and 1.39 (95% CI, 1.00–1.94) for 365-day all-cause mortality. Restricted cubic spline analyses supported a generally increasing risk of death with a higher FAR at both time points, without strong evidence of marked nonlinearity. CONCLUSIONS: Among older adults hospitalized with pneumonia, a higher FAR at admission was associated with increased 30-day and 365-day all-cause mortality, with a stronger association for short-term mortality. FAR may represent a simple, routinely available biomarker of adverse prognosis in this population, but prospective studies are needed to confirm its clinical utility. TRIAL REGISTRATION: Not applicable. This retrospective study was not prospectively registered. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12879-026-12520-6.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。